NITE - Nightstar Therapeutics plc

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
25.41
0.00 (0.00%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close25.41
Open25.43
Bid0.00 x 1800
Ask0.00 x 36100
Day's Range25.40 - 25.44
52 Week Range9.59 - 29.55
Volume40
Avg. Volume159,621
Market Cap852.155M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • GlobeNewswire20 days ago

    Biogen Completes Acquisition of Nightstar Therapeutics for Approximately $800 Million

    Nasdaq: NITE), a clinical-stage gene therapy company, which is focused on adeno-associated virus (AAV) treatments for inherited retinal disorders. As a result of the acquisition, Biogen now has added two mid- to late-stage clinical assets, as well as preclinical programs, in ophthalmology.

  • GlobeNewswire22 days ago

    Nightstar Therapeutics plc Court Approval Received in Connection With Acquisition by Biogen

    Nightstar Therapeutics plc (“Nightstar”) is pleased to announce that the High Court of Justice of England and Wales today sanctioned the scheme of arrangement under Part 26 of the Companies Act pursuant to which Tungsten Bidco Limited, a newly-incorporated company and wholly-owned indirect subsidiary of Biogen Inc., will acquire the entire issued and to be issued share capital of Nightstar (the “Acquisition”). All Conditions to the Acquisition have now been satisfied or waived other than delivery to the Registrar of Companies of England and Wales of a copy of the Court Order, which is expected to take place on 7 June 2019, at which point the Scheme will become Effective. Full details of the Acquisition are set out in the combined circular and proxy statement dated 9 April 2019 (the “Scheme Document”).

  • GlobeNewswire29 days ago

    Nightstar Therapeutics plc Update to Timetable Relating to the Acquisition by Biogen

    Nightstar Therapeutics plc (“Nightstar”) is pleased to announce an update to the expected timetable of events relating to the scheme of arrangement (the “Scheme”) pursuant to which Tungsten Bidco Limited, a newly-incorporated company and wholly-owned indirect subsidiary of Biogen Inc., will acquire the entire issued and to be issued share capital of Nightstar. The Scheme remains subject to certain conditions including sanction by the Court at the Court Hearing, which will now take place on 5 June 2019 (as opposed to 6 June 2019 as previously announced), and the delivery of a copy of the Court Order to the Registrar of Companies. Subject to the Scheme receiving the sanction of the Court and the delivery of a copy of the Court Order to the Registrar of Companies, the Scheme is still expected to become effective on 7 June 2019.

  • GlobeNewswire2 months ago

    Nightstar Therapeutics PLC Shareholders Approve Scheme of Arrangement for Acquisition By Biogen at General Meeting and Court Meeting Held on 8 May 2019

    Nightstar Therapeutics plc ("Nightstar") is pleased to announce that, at the General Meeting and the Court Meeting held earlier today in connection with the recommended acquisition of the entire issued and to be issued share capital of Nightstar by Tungsten Bidco Limited, a newly-incorporated company and wholly-owned indirect subsidiary of Biogen Inc., all resolutions proposed were passed by the requisite majorities and accordingly the Scheme was approved. Details of the resolutions passed are set out in the notices of General Meeting and Court Meeting at pages ix to xiii and vi to viii respectively of the combined circular and proxy statement dated 9 April 2019 (the "Scheme Document"). The detailed voting results in relation to the General Meeting and Court Meeting are set out below.

  • GlobeNewswire2 months ago

    Leading Proxy Advisory Firms ISS and Glass Lewis Recommend Nightstar Shareholders Vote “FOR” Proposed Acquisition by Biogen

    Nightstar Therapeutics plc ("Nightstar") (NITE) today announced that both leading independent proxy advisory firms, Institutional Shareholder Services Inc. (“ISS”) and Glass Lewis & Co. (“Glass Lewis”), have recommended that Nightstar shareholders vote "FOR" the proposals relating to the proposed acquisition of Nightstar by an affiliate of Biogen Inc. (“Biogen”). To become effective, the transaction must be approved by Nightstar shareholders at a special General Meeting and at a Court Meeting convened by the High Court of Justice in England and Wales. Both the General Meeting and the Court Meeting will be held at the offices of Nightstar’s solicitor, Skadden, Arps, Slate, Meagher & Flom LLP at 40 Bank Street, London, United Kingdom E14 5DS.

  • PR Newswire2 months ago

    Lifshitz & Miller LLP Announces Investigation of Advanced Disposal Services, Inc., Boston Scientific Corporation, Cavco Industries, Inc., Evoqua Water Technologies Corp., HomeFed Corporation, KeyW Holding Corporation, Level Brands, Inc., and Nightstar Therapeutics plc.

    NEW YORK , April 23, 2019 /PRNewswire/ -- Advanced Disposal Services, Inc. (ADSW) Lifshitz & Miller  announces investigation into possible breach of fiduciary duties in connection with the proposed sale ...

  • GlobeNewswire2 months ago

    Nightstar Therapeutics plc Announcement of Expiry of HSR Waiting Period and Satisfaction of Antitrust Condition

    Nightstar Therapeutics plc ("Nightstar") today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, with respect to the recommended acquisition of the entire issued and to be issued share capital of Nightstar by Tungsten Bidco Limited ("Bidco"), a newly-incorporated company and wholly-owned subsidiary of Biogen Switzerland Holdings GmbH (the "Acquisition"). Nightstar has also received notice from Bidco’s representatives that the German Federal Cartel Office will not assert jurisdiction to review the Acquisition.

  • GlobeNewswire2 months ago

    Nightstar (NITE) Merger Investigation: Halper Sadeh LLP Announces Investigation into Whether the Sale of Nightstar Therapeutics Plc is Fair to Nightstar Shareholders – NITE

    Halper Sadeh LLP, a global investor rights law firm, announces it is investigating whether the sale of Nightstar Therapeutics plc (“Nightstar” or the “Company”) (NITE) to Biogen Inc. (“Biogen”) is fair to Nightstar shareholders. If you are a Nightstar shareholder and would like to discuss your legal rights and options, please visit Nightstar (NITE) Merger Investigation or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com.

  • GlobeNewswire3 months ago

    Recommended Acquisition of Nightstar Therapeutics plc by Tungsten Bidco Limited, a Wholly-Owned Subsidiary of Biogen Switzerland Holdings GmbH; Posting of Scheme Document

    On 4 March 2019, the board of Nightstar Therapeutics plc ("Nightstar") and Biogen Switzerland Holdings GmbH ("Bidder"), a subsidiary of Biogen, Inc., announced that they had reached agreement on the terms of a recommended acquisition whereby the entire issued and to be issued share capital of Nightstar will be acquired by Tungsten Bidco Limited ("Bidco", a newly-incorporated company and wholly-owned subsidiary of Bidder) (the "Acquisition"). The Acquisition is to be effected by means of a Court-sanctioned scheme of arrangement under Part 26 of the Companies Act 2006 (the "Scheme") and is subject to the terms and conditions set out in the scheme document relating to the Acquisition (the "Scheme Document").

  • PR Newswire3 months ago

    INVESTOR ALERT: Monteverde & Associates PC is Investigating the Recently Announced Acquisition

    NEW YORK , April 1, 2019 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York ...

  • ACCESSWIRE4 months ago

    Rare Disease Therapies Draw Big Biopharma's Interest

    HENDERSON, NV / ACCESSWIRE / March 8, 2019 / The past few weeks have been busy with big bio taking over smaller biotechs developing novel therapies. Roche (RHHBY) said it would spend $4.8 billion in a ...

  • GlobeNewswire4 months ago

    Nightstar Therapeutics plc reaches agreement to be acquired by Biogen

    Nightstar Therapeutics plc ("Nightstar") (NITE), a clinical-stage gene therapy company developing treatments for rare inherited retinal diseases and Biogen Inc. ("Biogen") are pleased to announce that they have reached agreement on the terms of a recommended acquisition whereby the entire issued and to be issued share capital of Nightstar will be acquired by Tungsten Bidco Limited (a newly-incorporated company and wholly-owned subsidiary of Biogen Switzerland Holdings GmhH (“Bidder”)). It is intended that the Acquisition will be implemented by means of a U.K. Court-sanctioned scheme of arrangement under Part 26 of the U.K. Companies Act 2006. Under the terms of the Acquisition, Nightstar Shareholders will be entitled to receive USD 25.50 in cash for each Nightstar Share.

  • GlobeNewswire7 months ago

    Nightstar Announces Planned Initiation of Phase 2/3 Expansion Study in XIRIUS Trial for NSR-RPGR in XLRP and Reports Third Quarter 2018 Financial Results

    Phase 2/3 Expansion Study to Include No-Sham Control Arm in Alignment with FDA Draft Guidance on Development of Gene Therapy Products for Retinal Disorders Preliminary Efficacy.

  • GlobeNewswire8 months ago

    Nightstar Therapeutics to Participate in Multiple Conferences in November

    WALTHAM, Mass. and LONDON, Nov. 08, 2018 -- Nightstar Therapeutics plc (NASDAQ:NITE), a clinical-stage gene therapy company developing treatments for rare inherited retinal.